Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors

Bone Marrow Transplantation volume 31, pages 767–773 (2003)Cite this article

Summary:

A total of 30 multiple myeloma patients (M=23, F=7; age 31–55 years, median 48) were allografted with peripheral blood stem cells (PBSC) from HLA-identical siblings. Time to transplantation was 3–107 months (median 8). Prior chemotherapy lines varied from 1 to 6 (median 1). Four patients were in complete remission (CR), 11 in partial remission (PR), 13 were considered to be nonresponders, and two had progressive disease. Most were conditioned with busulfan–melphalan. PBSC were collected by apheresis after G-CSF or sequential GM-CSF and G-CSF. The patients were grafted with 4.4–24.1 × 106/kg CD34+ (median 7.9) and 0.9–7.9 × 108/kg CD3+ cells (median 2.3). GVHD prophylaxis was methotrexate–cyclosporine. Engraftment was complete and rapid. Grades II–IV acute GVHD (aGVHD) developed in 16 (53%), but was grade III–IV only in five (17%); chronic GVHD (cGVHD) developed in 17 out of the 24 evaluable patients (71%). A total of 18 patients (71%) attained CR after transplantation. TRM was 30% overall, 16% at 100 days. There was only one relapse. Overall survival and event-free survival at 73 months were 60% and 67%, respectively. PCR negativity for IgH-gene rearrangement occurred in all persistently CR patients studied. PBSC allograft can induce long remissions, because of profound suppression of the neoplastic clone that is probably linked to the antitumor effect of cGVHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Eng J Med 1996; 335: 91–97.

    Article  CAS  Google Scholar 

  2. Majolino I, Vignetti M, Meloni G et al. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Haematologica 1999; 84: 844–852.

    CAS  PubMed  Google Scholar 

  3. Tricot G, Spencer T, Sawyer J et al. Predicting long-term (> or =5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 2002; 116: 211–217.

    Article  PubMed  Google Scholar 

  4. Corradini P, Voena C, Tarella C et al. Molecular and clinical remissions in multiple myeloma: the role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17: 208–215.

    Article  CAS  PubMed  Google Scholar 

  5. Gahrton G, Svennson H, Bjorkstrand B et al. Syngeneic bone marrow transplantation in multiple myeloma. Bone Marrow Transplant 1997; 19 (Suppl. 1): S88.

    Google Scholar 

  6. Bensinger WI, Buckner CD, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood 1996; 88: 2787–2793.

    CAS  PubMed  Google Scholar 

  7. Gahrton G, Tura S, Ljungman P et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312–1322.

    Article  CAS  PubMed  Google Scholar 

  8. Mehta J, Tricot G, Jagannath S et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998; 21: 887–892.

    Article  CAS  PubMed  Google Scholar 

  9. Bjorkstrand B, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711–4718.

    CAS  PubMed  Google Scholar 

  10. Fermand JP, Chevret S, Ravaud P et al. High-dose chemo-radiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood 1993; 82: 2005–2009.

    CAS  PubMed  Google Scholar 

  11. Majolino I, Corradini P, Scimè R et al. Allogeneic transplantation of unmanipulated PBSC in patients with multiple myeloma. Bone Marrow Transplant 1998; 22: 449.

    Article  CAS  PubMed  Google Scholar 

  12. Durie BGM, Salmon SE . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36: 842–854.

    Article  CAS  PubMed  Google Scholar 

  13. Alexanian R, Barlogie B, Tucker S . VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990; 33: 86–89.

    Article  CAS  PubMed  Google Scholar 

  14. Palumbo A, Pileri A, Triolo S et al. Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients. Bone Marrow Transplant 1997; 19: 23–29.

    Article  CAS  PubMed  Google Scholar 

  15. Majolino I, Scimè R, Vasta S et al. Mobilization and collection of PBSC in healthy donors: comparison between two schemes of rhG-CSF administration. Eur J Haematol 1996; 57: 214–221.

    Article  CAS  PubMed  Google Scholar 

  16. Alegre A, Lamana M, Arranz R et al. Busulfan and melphalan as conditioning regimen for autologous peripheral blood stem cell transplantation in multiple myeloma. Br J Haematol 1995; 91: 380–386.

    Article  CAS  PubMed  Google Scholar 

  17. van der Bij W, Torensma R, van Son WJ et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leukocytes. J Med Virol 1988; 25: 179–188.

    Article  CAS  PubMed  Google Scholar 

  18. Corradini P, Boccadoro M, Voena C, Pileri A . Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined Cmu sequence in immunoglobulin (IgG) and (IgA) secreting multiple myelomas. J Exp Med 1993; 178: 1091–1096.

    Article  CAS  PubMed  Google Scholar 

  19. Mehta J, Powles R, Treleaven J et al. Number of nucleated cells infused during allogeneic and autologous bone marrow transplantation: an important modifiable factor influencing outcome. Blood 1997; 90: 3808–3810.

    CAS  PubMed  Google Scholar 

  20. Mavroudis D, Read E, Cottler-Fox M et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223–3229.

    CAS  PubMed  Google Scholar 

  21. Bacigalupo A, Piaggio G, Podestà M et al. Influence of marrow CFU-GM content on engraftment and survival after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 221–226.

    CAS  PubMed  Google Scholar 

  22. Kulkarni S, Powles RL, Treleaven JG et al. Impact of previous high-dose therapy on outcome after allografting for multiple myeloma. Bone Marrow Transplant 1999; 23: 675–680.

    Article  CAS  PubMed  Google Scholar 

  23. Gahrton G, Svensson H, Cavo M et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209–216.

    Article  CAS  PubMed  Google Scholar 

  24. Hallek M, Bergsagel PL, Anderson KC . Multiple myeloma: increasing evidence for a multistep transformation process. Blood 1998; 91: 3–21.

    CAS  PubMed  Google Scholar 

  25. Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115–1123.

    Article  CAS  PubMed  Google Scholar 

  26. Majolino I, Saglio G, Scimè R et al. High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1996; 17: 555–560.

    CAS  PubMed  Google Scholar 

  27. Storek J, Gooley T, Siadak M et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood 1997; 90: 4705–4709.

    CAS  PubMed  Google Scholar 

  28. Bertz H, Burger JA, Kunzmann R et al. Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect. Leukemia 1997; 11: 281–283.

    Article  CAS  PubMed  Google Scholar 

  29. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997; 90: 4206–4211.

    CAS  PubMed  Google Scholar 

  30. Kwak LW, Taub DD, Duffey PLl et al. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 1995; 345: 1016–1020.

    Article  CAS  PubMed  Google Scholar 

  31. Chiriva-Internati M, Du J, Cannon M et al. Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathway. Br J Haematol 2001; 112: 410–420.

    Article  CAS  PubMed  Google Scholar 

  32. Lim SH, Badros A, Lue C, Barlogie B . Distinct T-cell clonal expansion in the vicinity of tumor cells in plasmacytoma. Cancer 2001; 91: 900–908.

    Article  CAS  PubMed  Google Scholar 

  33. Powles R, Mehta J, Kulkarni S et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355: 1231–1237.

    Article  CAS  PubMed  Google Scholar 

  34. Elmaagacli AH, Beelen DW, Opalka B et al. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow. Blood 1999; 94: 384–389.

    CAS  PubMed  Google Scholar 

  35. Elmaagacli AH, Basoglu S, Peceny R et al. Improved disease-free-survival after transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 2002; 99: 1130–1135.

    CAS  PubMed  Google Scholar 

  36. Tricot G, Vesole DH, Jagannath S et al. Graft-versus-myeloma effect: proof of a principle. Blood 1996; 87: 1196–1198.

    CAS  PubMed  Google Scholar 

  37. Libura J, Hoffmann T, Passweg J et al. Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 1999; 24: 925–927.

    Article  CAS  PubMed  Google Scholar 

  38. Alyea E, Weller E, Schlossman R et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood 2001; 98: 934–939.

    Article  CAS  PubMed  Google Scholar 

  39. Kroger N, Kruger W, Renges H et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br J Haematol 2001; 112: 421–423.

    Article  CAS  PubMed  Google Scholar 

  40. Corradini P, Cavo M, Lokhorst H et al. Allogeneic transplantation of hematopoietic cells is able to induce a durable molecular remission in myeloma patients. Blood 1999; 94 (Suppl. 1): 346a.

    Google Scholar 

  41. Cavo M, Terragna C, Martinelli G et al. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 2000; 96: 355–357.

    CAS  PubMed  Google Scholar 

  42. Maloney DG, Sahebi F, Stockerl-Goldstein KE et al. Combining an allogeneic graft-vs-myeloma effect with high-dose autologous stem cell rescue in the treatment of multiple myeloma. Blood 2001; 98 (Suppl. 1): 434a.

    Google Scholar 

Download references

Acknowledgements

The present work was supported in part by a grant of the Associazione Italiana per la Ricerca sul Cancro (AIRC).

Author information

Authors and Affiliations

  1. Hematology and Bone Marrow Transplantation Unit, Azienda Ospedaliera S.Camillo-Forlanini, Roma

    I Majolino

  2. Bone Marrow Transplantation Unit, Istituto Nazionale Tumori, Milan

    P Corradini

  3. Division of Hematology, Ospedale V.Cervello, Palermo

    R Scimè, R Marcenò & A Santoro

  4. Hospital and University Divisions of Hematology, Ospedale S.Giovanni Battista, Torino

    M Falda, C Tarella, M Boccadoro & A Pileri

  5. Department of Hematology, Bone Marrow Transplantation Unit, Ospedale di Careggi, Florence

    A Bosi

  6. Unit of Onco-hematology, Casa di Cura ‘La Maddalena’, Palermo

    M Musso

  7. Hematology Department, Ospedale di Torrette, Ancona, Italy

    A Olivieri

Authors
  1. I Majolino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Corradini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Scimè
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Falda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Bosi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Tarella
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Musso
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Olivieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Boccadoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R Marcenò
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Santoro
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A Pileri
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to I Majolino.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Majolino, I., Corradini, P., Scimè, R. et al. High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors. Bone Marrow Transplant 31, 767–773 (2003). https://doi.org/10.1038/sj.bmt.1703924

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703924

Keywords

This article is cited by

Search

Advanced search

Quick links